<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl7">
 <label>Table 7</label>
 <caption>
  <p>Dosage, experimental model, pharmacological action and mechanism of Atractylodis Rhizoma extracts.</p>
 </caption>
 <alt-text id="alttext1175">Table 7</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Pharmacology</th>
    <th>Pharmacological effects</th>
    <th>Substances and dosages</th>
    <th>Experimental model</th>
    <th>Mechanisms</th>
    <th>Ref.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="5">Improving gastrointestinal function</td>
    <td align="left">Stimulating gastric emptying or small intestinal motility</td>
    <td align="left">The extract (500 or 1000 mg/kg) and β-eudesmol (50 or 100 mg/kg)</td>
    <td align="left">Atropine-, dopamine-, 5-hydroxytryptamine-treated mice</td>
    <td align="left">Inhibiting the dopamine D2 and 5-HT3 receptor</td>
    <td align="left">
     <xref rid="bib52" ref-type="bibr">Kimura and Sumiyoshi (2012)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Inhibiting of gastric ulcer</td>
    <td align="left">n-butanol extract
     <break/>0.18 g/kg
    </td>
    <td align="left">Rats</td>
    <td align="left">Improving blood circulation in ulcer, promoting DNA, RNA and protein synthesis</td>
    <td align="left">
     <xref rid="bib83" ref-type="bibr">Piao and Piao (1996)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Anti-gastrointestinal mucosal injury</td>
    <td align="left">Atractylenolide I (ATL-I) 5 and 10 μM</td>
    <td align="left">IEC-6 cell</td>
    <td align="left">Promoting IEC-6 cell proliferation and migration; increasing polyamines content, and enhancing TRPC1 and PLC-γ1 mRNA and protein expression</td>
    <td align="left">
     <xref rid="bib95" ref-type="bibr">Song et al. (2017)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Resisting gastric ulcer</td>
    <td align="left">Hinesol
     <break/>IC50: 5.8*10
     <sup>5</sup> M
    </td>
    <td align="left">Porcine gastric membrane vesicles</td>
    <td align="left">Inhibiting H
     <sup>+</sup>, K
     <sup>+</sup>-ATPase and Mg
     <sup>2+</sup>-ATPase and Ca
     <sup>2+</sup>-ATPase activity
    </td>
    <td align="left">
     <xref rid="bib91" ref-type="bibr">Satoh et al. (2000)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Anti-gastric ulcer</td>
    <td align="left">
     <italic>A. lancea</italic> 2.5 g/kg
    </td>
    <td align="left">Acetic acid imitated rats</td>
    <td align="left">The gastroprotective effects were mediated by up-regulating trefoil factor 2 and epidermal growth factor</td>
    <td align="left">
     <xref rid="bib135" ref-type="bibr">Yu et al. (2015)</xref>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="4">Immunomodulatory activity</td>
    <td align="left">Immunostimulatory effects</td>
    <td align="left">The boiling water extract
     <break/>1.0 mg/mL
    </td>
    <td align="left">Murine normal colonic epithelial MCE301 cells</td>
    <td align="left">Inducing secretion of granulocyte colony-stimulating factor</td>
    <td align="left">
     <xref rid="bib94" ref-type="bibr">Shimato et al. (2018)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Immunomodulatory activity</td>
    <td align="left">Acidic polysaccharide (ALP-3) 50, 100, 250, 500, 1000, 2000 μg/mL</td>
    <td align="left">Murine RAW264.7 macrophage cell line</td>
    <td align="left">Stimulating macrophage proliferation, and stimulating phagocytic, NO and cytokines production on RAW264.7 cells</td>
    <td align="left">
     <xref rid="bib86" ref-type="bibr">Qin et al. (2019)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Intestinal immune system modulating activity</td>
    <td align="left">ALP-1 and ALP-3 50, 100, 250, 500, 1000, 2000 μg/mL</td>
    <td align="left">Peyer's patch cells</td>
    <td align="left">Activating T cells in Peyer patch cells and promoting the production of CSF</td>
    <td align="left">
     <xref rid="bib86" ref-type="bibr">Qin et al. (2019)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Intestinal immune system modulating activity</td>
    <td align="left">Polysaccharides
     <break/>100 μg/mL
    </td>
    <td align="left">Peyer's patch cells</td>
    <td align="left">Regulating intestinal immune system</td>
    <td align="left">
     <xref rid="bib134" ref-type="bibr">Yu et al. (1998)</xref>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="16">Anti-tumor activity</td>
    <td align="left">Inhibitory effect on human gastric cancer cells</td>
    <td align="left">Water extract of the 
     <italic>A. lancea</italic> 0.0625, 0.125, 0.25, 0.5, and 1 mg/mL
    </td>
    <td align="left">BGC-823 and SGC-7901 cells</td>
    <td align="left">Inhibiting the growth of BGC-823 and SGC-7901 cells</td>
    <td align="left">
     <xref rid="bib141" ref-type="bibr">Zhao et al. (2014)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Anti-leukemia</td>
    <td align="left">Atractylenolide I (ATL-I) 3.13–100 μg/mL</td>
    <td align="left">Human K562 CML, U937 AML and Jurkat T lymphoma cells</td>
    <td align="left">Inducing apoptosis and differentiation of macrophage lineage</td>
    <td align="left">
     <xref rid="bib33" ref-type="bibr">Huang et al. (2016)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Anti-melanoma effects</td>
    <td align="left">Atractylenolide I (ATL-I) 40, 60, 80, 100, 120, 150 μM</td>
    <td align="left">Human A375, Hs294T and SK-MEL-5 melanoma cells</td>
    <td align="left">Inhibiting phospho-janus kinase 2, phospho-signal transducer and activator of transcription 3, matrix metalloproteinase-2 and -9</td>
    <td align="left">
     <xref rid="bib23" ref-type="bibr">Fu et al. (2018)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Antimelanoma effects</td>
    <td align="left">Atractylenolide II (ATL-II) 12.5, 25 mg/kg</td>
    <td align="left">B16 xenograft mouse</td>
    <td align="left">Suppressing STAT3 activation and tumor growth</td>
    <td align="left">
     <xref rid="bib22" ref-type="bibr">Fu et al. (2014)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Antigastric carcinoma</td>
    <td align="left">ATL-II 50, 100, 200, 400 μM</td>
    <td align="left">Human gastric carcinoma cell lines HGC-27 and AGS</td>
    <td align="left">Modulating Akt/ERK signaling pathway to inhibit cell proliferation, motility and inducing apoptosis</td>
    <td align="left">
     <xref rid="bib103" ref-type="bibr">Tian and Yu (2017)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Antitumor activity</td>
    <td align="left">Atractylenolide III (ATL-III) 1, 10, 100 μM</td>
    <td align="left">HMC-1 cell</td>
    <td align="left">Inhibiting mast cell proliferation, phosphorylated signal transducer, IL-13, proinflammatory cytokines and activator of transcription</td>
    <td align="left">
     <xref rid="bib130" ref-type="bibr">Yoou et al. (2017)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Antitumor activity</td>
    <td align="left">ATL-III 100 μM</td>
    <td align="left">LAD2 human mast cell</td>
    <td align="left">Inhibiting mast cell proliferation and the production of inflammatory cytokine</td>
    <td align="left">
     <xref rid="bib130" ref-type="bibr">Yoou et al. (2017)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Antitumor activity</td>
    <td align="left">Hinesol 5, 10, 25, 50, 100 μM</td>
    <td align="left">Human leukemia HL-60 cells</td>
    <td align="left">Hinesol induced apoptosis through the JNK signaling pathway in HL-60 cells</td>
    <td align="left">
     <xref rid="bib69" ref-type="bibr">Masuda et al. (2015)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Anti-cholangiocarcinoma</td>
    <td align="left">β-eudesmol
     <break/>IC50: 39.33 mg/mL
    </td>
    <td align="left">The CCA cell lines, and normal human cell line</td>
    <td align="left">Promoting cell cycle arrest at G1 phase, and inducing cell apoptosis through activation of caspase-3/7</td>
    <td align="left">
     <xref rid="bib57" ref-type="bibr">Kotawong et al. (2018)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Anti-hepatocellular carcinoma</td>
    <td align="left">β-eudesmol
     <break/>IC50: 16.51 ± 1.21–24.57 ± 2.75 μg/mL
    </td>
    <td align="left">B16–F10 and HepG2 cell lines</td>
    <td align="left">Inducing tumor cell death by caspase-mediated apoptosis pathways</td>
    <td align="left">Bomfim et al. (2013)</td>
   </tr>
   <tr>
    <td align="left">Anti-multiple myeloma cells</td>
    <td align="left">β-sitosterol 0, 6.25, 12.5, 25, 50, 100 mM</td>
    <td align="left">Human multiple myeloma U266 and MM1S cell</td>
    <td align="left">Increasing the sub-G1 apoptotic population, activating caspase-9 and -3</td>
    <td align="left">Sook et al. (2014)</td>
   </tr>
   <tr>
    <td align="left">Anti-tumor activity</td>
    <td align="left">β-eudesmol 10–100 mM</td>
    <td align="left">HeLa, SGC-7901, and BEL-7402</td>
    <td align="left">Inhibiting angiogenesis by suppressing CREB activation in the growth factor signaling pathway</td>
    <td align="left">
     <xref rid="bib67" ref-type="bibr">Ma et al. (2008)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Inhibiting of Cholangiocarcinoma</td>
    <td align="left">β-eudesmol (0, 1, 10, 30, 100 μM), dicoumarol (1 μM), 5-FU (0, 3, 10, 30, 100 μM), DOX (0, 0.1, 0.01, 1, 10 μM)</td>
    <td align="left">Human CCA cell line, KKU-100</td>
    <td align="left">Enhancing chemotherapeutic effects of 5-fluorouracil and doxorubicin in the high NQO1-expressing human CCA cell line, NQO1-KKU-100</td>
    <td align="left">
     <xref rid="bib96" ref-type="bibr">Srijiwangsa et al. (2018)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Inhibiting of lung and colon cancer</td>
    <td align="left">β-eudesmol 5–100 μM</td>
    <td align="left">Human lung (A549) cells, colon (HT29 and Caco-2) cells</td>
    <td align="left">Inhibiting proliferation of tumor cells and superoxide production; inhibiting adhesion and migration of A549 and HT29 cell</td>
    <td align="left">
     <xref rid="bib92" ref-type="bibr">Sghaier et al. (2016)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Anti-angiogenic mechanism and anti-tumor activity</td>
    <td align="left">β-eudesmol (2.5–5 mg/kg)</td>
    <td align="left">Implanting H22 and S180 mice tumor cells into oxters of 7-week-old KM mice</td>
    <td align="left">Suppressing CREB activation in growth factor signaling pathway</td>
    <td align="left">
     <xref rid="bib67" ref-type="bibr">Ma et al. (2008)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Inhibiting angiogenesis</td>
    <td align="left">β-eudesmol 10–100 μM</td>
    <td align="left">Porcine brain microvascular endothelial cells, human dermal microvascular endothelial cells</td>
    <td align="left">The blockade of the ERK signaling pathway</td>
    <td align="left">
     <xref rid="bib105" ref-type="bibr">Tsuneki et al. (2005)</xref>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="6">Anti-inflammatory activity</td>
    <td align="left">Anti-inflammatory effects in vitro</td>
    <td align="left">AR methanol extract 100 μg/mL</td>
    <td align="left">Murine macrophage-like cell line RAW264.7 cells</td>
    <td align="left">Inhibiting the production of NO</td>
    <td align="left">
     <xref rid="bib94" ref-type="bibr">Shimato et al. (2018)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Anti-inflammatory effect</td>
    <td align="left">ATL-III 1–100 μM, LPS 1 μg/mL</td>
    <td align="left">The murine macrophage cell line RAW264.7</td>
    <td align="left">Suppressing the release of NO, PGE2, TNF-α and IL-6 related to the NF-κB- and MAPK signaling pathways</td>
    <td align="left">
     <xref rid="bib37" ref-type="bibr">Ji et al. (2016)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Improving intestinal inflammation and cooccurring dysmotility</td>
    <td align="left">Atractylodin 10.0 mg/kg</td>
    <td align="left">Diarrheaprominent rats were established by acetic acid and restraint stress; constipation-prominent rats were established by cool water</td>
    <td align="left">Reducing pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 in the plasma and inhibiting the expression of inflammatory mediators iNOS and NF-κB in jejunal segments in both CP and DP rats.</td>
    <td align="left">
     <xref rid="bib133" ref-type="bibr">Yu et al. (2017)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Anti-inflammatory effects</td>
    <td align="left">Water extracts of 
     <italic>A. lancea</italic> rhizomes 100, 200 mg/kg
    </td>
    <td align="left">Male C57BL/6 mice</td>
    <td align="left">Inducing the hepatic expression of CYP3A</td>
    <td align="left">Yuan et al. (2017)</td>
   </tr>
   <tr>
    <td align="left">Alleviating LPS-induced inflammatory responses</td>
    <td align="left">Atractylodin 40 or 80 mg/kg</td>
    <td align="left">Lipopolysaccharide (LPS)-induced inflammatory rates</td>
    <td align="left">Suppression of nucleotide-binding domain-like receptor protein 3 inflammasome and toll-like receptor 4 activation</td>
    <td align="left">
     <xref rid="bib101" ref-type="bibr">Tang et al. (2018)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Ameliorate colitis</td>
    <td align="left">β-sitosterol and stigmasterol 0.4%</td>
    <td align="left">Dextran sulfate sodium (DSS)-induced colitis in C57BL/6J male mice</td>
    <td align="left">Suppressing the activation of inflammatory master regulator NF-κB. Stigmasterol significantly lowered colonic inflammation score and the expression of cyclooxygenase-2 and colony stimulating factor-1</td>
    <td align="left">
     <xref rid="bib19" ref-type="bibr">Feng et al. (2017)</xref>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="2">Anti-bacterial activity</td>
    <td align="left">Antimycotic effect</td>
    <td align="left">AR 0.5–10.0%</td>
    <td align="left">
     <italic>Trichophyton tonsuraus</italic>, 
     <italic>Microsporum gypseum</italic> et al.
    </td>
    <td align="left">This drug had apparent fungi action</td>
    <td align="left">
     <xref rid="bib129" ref-type="bibr">Yin et al. (2000)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Combating multidrug resistant strains</td>
    <td align="left">Stigmasterol 1 μg/disc, or in combination (1 μg/disc ampicillin + 1 μg/disc stigmasterol)</td>
    <td align="left">2 g-positive bacteria and 2 g-negative bacteria</td>
    <td align="left">Synergistic effects of stigmasterol and ampicillin against β-lactamase producing clinical isolates</td>
    <td align="left">
     <xref rid="bib128" ref-type="bibr">Yenn et al. (2017)</xref>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="9">Other activities</td>
    <td align="left">Protective effects of acute lung injury</td>
    <td align="left">LPS + AO-I (5, 10 and 20 mg/kg), LPS + VGX-1027 (0.5 mg/mouse)</td>
    <td align="left">LPS-induced acute lung injury mouse model</td>
    <td align="left">Inhibiting of TLR4 expression and NF-κB activation</td>
    <td align="left">
     <xref rid="bib138" ref-type="bibr">Zhang et al. (2015)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Antiasthmatic properties</td>
    <td align="left">Stigmasterol 10–100 mg/kg</td>
    <td align="left">Ovalbumin-induced Guinea pigs</td>
    <td align="left">Reducing the proliferation of eosinophils, lymphocytes, and monocytes while reducing peribronchiolar, perivascular, and alveolar infiltration of inflammatory cells</td>
    <td align="left">
     <xref rid="bib2" ref-type="bibr">Antwi et al. (2017)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Treatment of hallucinations of dementia</td>
    <td align="left">Atractylenolide III 0.03, 0.15, 0.75 mg/kg;
     <break/>β-eudesmol 0.4, 2.0, 10 mg/kg
    </td>
    <td align="left">1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced head-twitch mice</td>
    <td align="left">Active constituents contributing to the anti-hallucination effects of Byaku- and So-jutsu against serotonin receptors</td>
    <td align="left">
     <xref rid="bib73" ref-type="bibr">Murayama et al. (2014)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Neuroprotective activity</td>
    <td align="left">Atractylenolide III 0.6, 1.2 and 2.4 mg/kg/day</td>
    <td align="left">Chronic high-dose homocysteine administration induced learning and memory impairment in rats</td>
    <td align="left">Decreasing homocysteine-induced reactive oxygen species formation and restored homocysteine-induced decrease of phosphorylated protein kinase C expression level</td>
    <td align="left">
     <xref rid="bib140" ref-type="bibr">Zhao et al. (2015)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Autonomic nerve activity</td>
    <td align="left">β-eudesmol 1.6, 1.8, 2.3, 2.4 ng/mL</td>
    <td align="left">Male Wistar rats (300–350 g)</td>
    <td align="left">Suppressing ASNA, partly through TRPA1 and the afferent vagus nerve</td>
    <td align="left">
     <xref rid="bib81" ref-type="bibr">Ohara et al. (2018)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Influenza A virus treatment</td>
    <td align="left">Atractylon treatment at doses of 10–40 mg/kg</td>
    <td align="left">Influenza a virus (IAV) caused pneumonia in mice</td>
    <td align="left">Upregulating the expression of Τoll-like receptor 7, MyD88, tumor necrosis factor receptor-associated factor 6 and IFN-β mRNA but downregulating NF-κB p65 protein expression in the lung tissues of IAV-infected mice</td>
    <td align="left">
     <xref rid="bib8" ref-type="bibr">Cheng et al. (2016)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Anti-diabetic activity</td>
    <td align="left">Metformin 200 mg/kg, stigmasterol 50, 100 mg/kg</td>
    <td align="left">Rat L6 cells</td>
    <td align="left">Enhancing the GLUT4 expression in L6 cells, skeletal muscle and white adipose tissue</td>
    <td align="left">
     <xref rid="bib111" ref-type="bibr">Wang et al. (2017)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Anti-obesity effect</td>
    <td align="left">the ethanol extract of 
     <italic>Atractylodes lancea</italic> rhizome (250, 500 mg/kg)
    </td>
    <td align="left">A high-fat diet-induced obesity mice</td>
    <td align="left">Atractylodin showed the highest lipase inhibitory activity</td>
    <td align="left">
     <xref rid="bib42" ref-type="bibr">Jiao et al. (2014)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Anti-allergic activities</td>
    <td align="left">AR ethanol extracts 200 mg/day</td>
    <td align="left">Male NC/Nga mice</td>
    <td align="left">Inhibiting 5-LOX from RBL-1 cells</td>
    <td align="left">
     <xref rid="bib60" ref-type="bibr">Lim et al. (2012)</xref>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
